Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017

NORCROSS, Ga., Sept. 25, 2017 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced Peter G. Traber, M.D., the Company’s chief executive officer and chief medical officer was named Chair of the Conference for NASH Summit Europe 2017. The Summit, an industry nonalcoholic steatohepatitis (NASH) drug development forum, will take place at The Westin Grand Frankfurt in Frankfurt, Germany on October 10-12, 2017.

“Being named this year’s Chair of the Conference for NASH Summit Europe recognizes all the hard work that Galectin has done to make a breakthrough in this troubling disease,” says Dr. Traber. “With no approved treatment and a patient population in the millions and growing, NASH is a huge unmet medical need. NASH Summit Europe is an important conference where the top clinicians and scientists working on NASH can extensively discuss drug development challenges to improve drug efficacy, robustly diagnose patient populations, and identify novel targets that can translate to clinical practice.”

Focused exclusively on NASH and replete with leading industry experts, NASH Summit Europe is designed to provide the latest insight and connections to solve the challenges many face from drug discovery to late stage clinical development. The theme of this year’s conference is “Accelerate the Development of Your Nonalcoholic Steatohepatitis Drug Pipeline.”

“NASH has proven to be incredibly difficult to diagnose, in turn creating a difficult drug development process,” adds Traber. “For this reason, it is essential that both organizations developing a drug as well as developing novel non-invasive diagnostic tests collaborate to advance the treatment of NASH and accelerate the timelines to when effective therapies are available to patients.”  

As Chair of the Conference, Dr. Traber helped organize the internationally renowned academic and industrial speakers at this conference and will provide the opening and closing remarks on October 11 and 12.

About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are for treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.

Contacts:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected]